The design of the study will be very important. It suggests that they are recruiting from 30+ who were recently diagnosed. But the overall makeup of the study groups will be very important, along with the temporality to the infection. As Ivermectin is acting primarily as an anti-viral, administering it to people who are a week or more into the infection is pointless as they are by that time past the actual viral phase of the infection and are now fighting a battle against themselves. A better study would likely be to recruit a very large sample, 50000+ and study prophylactic protection of low dose Ivermectin. That is unlikely to happen though. ---- Another thing that will be important to be aware of is whether Duke or the researchers receive any financial incentives, or risk the loss of financial backing from certain pharmaceutical companies if their research finds the "wrong" answer.